Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talaporfin PDT plus nivolumab for chemotherapy-refractory advanced esophageal squamous cell carcinoma
jRCT1041200029Completed
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of talaporfin sodium and nivolumab in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: Progression-free survival. Started Apr 2021; status: completed.
02
Drugs
talaporfin sodiumnivolumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCT1041200029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041200029.